

Johan Hartman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5506696/johan-hartman-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|-------------------|-------------------------|----------------|----------------|
| 82 papers | 5,123 citations | 32 h-index | 71 g-index |
| 92 ext. papers | 6,256 ext. citations | 9.2 avg, IF | 5.5 L-index |

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 82 | Abstract P1-07-07: Endoresist: Prognostic and predictive gene profiles in endocrine-resistant breast cancers. <i>Cancer Research</i> , 2022 , 82, P1-07-07-P1-07-07 | 10.1 | |
| 81 | Abstract P3-02-06: A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer. <i>Cancer Research</i> , 2022 , 82, P3-02-06-P3-02-06 | 10.1 | |
| 80 | Abstract P1-02-03: Tumor-infiltrating lymphocytes but not HER2 copy number or ratio show prognostic value in trastuzumab-treated HER2-positive breast cancer. <i>Cancer Research</i> , 2022 , 82, P1-02-03-P1-02-03 | 10.1 | |
| 79 | Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. <i>Cancers</i> , 2022 , 14, 2615 | 6.6 | 2 |
| 78 | Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. <i>Npj Breast Cancer</i> , 2021 , 7, 144 | 7.8 | 0 |
| 77 | Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group. <i>Biomolecules</i> , 2021 , 11, | 5.9 | 3 |
| 76 | Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. <i>Cancers</i> , 2021 , 13, | 6.6 | 5 |
| 75 | TAp73 represses NF- κ B-mediated recruitment of tumor-associated macrophages in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118, | 11.5 | 6 |
| 74 | Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer. <i>ESMO Open</i> , 2021 , 6, 100076 | 6 | 0 |
| 73 | An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5557-5565 | 12.9 | 6 |
| 72 | The Importance of Sex in the Discovery of Colorectal Cancer Prognostic Biomarkers. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 4 |
| 71 | Molecular analyses of triple-negative breast cancer in the young and elderly. <i>Breast Cancer Research</i> , 2021 , 23, 20 | 8.3 | 3 |
| 70 | Predicting Molecular Phenotypes from Histopathology Images: A Transcriptome-Wide Expression-Morphology Analysis in Breast Cancer. <i>Cancer Research</i> , 2021 , 81, 5115-5126 | 10.1 | 1 |
| 69 | What do we still need to learn on digitally assessed biomarkers?. <i>EBioMedicine</i> , 2021 , 70, 103520 | 8.8 | 0 |
| 68 | Improved breast cancer histological grading using deep learning. <i>Annals of Oncology</i> , 2021 , | 10.3 | 5 |
| 67 | Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1360-1367 | 13.4 | 1 |
| 66 | Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020 , 6, 16 | 7.8 | 47 |

| | | | |
|----|---|------|-----|
| 65 | Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 161-175 | 4.4 | 16 |
| 64 | Artificial intelligence as the next step towards precision pathology. <i>Journal of Internal Medicine</i> , 2020 , 288, 62-81 | 10.8 | 80 |
| 63 | Three-dimensional single-cell imaging for the analysis of RNA and protein expression in intact tumour biopsies. <i>Nature Biomedical Engineering</i> , 2020 , 4, 875-888 | 19 | 9 |
| 62 | Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. <i>Molecular Oncology</i> , 2020 , 14, 951-963 | 7.9 | 9 |
| 61 | Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds. <i>Cancer Research</i> , 2020 , 80, 1538-1550 | 10.1 | 9 |
| 60 | CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1185-1198 | 15.9 | 70 |
| 59 | Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. <i>Nature Communications</i> , 2020 , 11, 3747 | 17.4 | 18 |
| 58 | Identification and targeting of selective vulnerability rendered by tamoxifen resistance. <i>Breast Cancer Research</i> , 2020 , 22, 80 | 8.3 | 3 |
| 57 | Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes. <i>Cancer Letters</i> , 2020 , 492, 54-62 | 9.9 | 17 |
| 56 | Next generation pathology: artificial intelligence enhances histopathology practice. <i>Journal of Pathology</i> , 2020 , 250, 7-8 | 9.4 | 11 |
| 55 | Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 795-805 | 4.4 | 18 |
| 54 | Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. <i>Nature Communications</i> , 2019 , 10, 2110 | 17.4 | 59 |
| 53 | PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer. <i>Nature Communications</i> , 2019 , 10, 3589 | 17.4 | 18 |
| 52 | CUTseq is a versatile method for preparing multiplexed DNA sequencing libraries from low-input samples. <i>Nature Communications</i> , 2019 , 10, 4732 | 17.4 | 8 |
| 51 | CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. <i>Scientific Reports</i> , 2019 , 9, 19384 | 4.9 | 10 |
| 50 | Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. <i>Cell</i> , 2018 , 173, 879-893.e13 | 56.2 | 427 |
| 49 | Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer. <i>Journal of Clinical Pathology</i> , 2018 , 71, 787-794 | 3.9 | 17 |
| 48 | Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). <i>BMC Cancer</i> , 2018 , 18, 174 | 4.8 | 14 |

| | | | |
|----|---|------|-----|
| 47 | Notch signaling promotes a HIF2 β -driven hypoxic response in multiple tumor cell types. <i>Oncogene</i> , 2018 , 37, 6083-6095 | 9.2 | 11 |
| 46 | Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1355-1370 | 15.9 | 78 |
| 45 | Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer. <i>Histopathology</i> , 2018 , 72, 974-989 | 7.3 | 44 |
| 44 | Digital image analysis in breast pathology-from image processing techniques to artificial intelligence. <i>Translational Research</i> , 2018 , 194, 19-35 | 11 | 128 |
| 43 | Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 $\frac{1}{2}$ years longitudinal data from the Stockholm-Gotland cancer registry. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 703-712 | 4.4 | 3 |
| 42 | A Zebrafish Model Discovers a Novel Mechanism of Stromal Fibroblast-Mediated Cancer Metastasis. <i>Clinical Cancer Research</i> , 2017 , 23, 4769-4779 | 12.9 | 51 |
| 41 | Differential expression of sex hormone receptors in abdominal aortic aneurysms. <i>Maturitas</i> , 2017 , 96, 39-44 | 5 | 17 |
| 40 | Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity. <i>Nature Biomedical Engineering</i> , 2017 , 1, 796-806 | 19 | 96 |
| 39 | Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling. <i>BMC Cancer</i> , 2017 , 17, 802 | 4.8 | 5 |
| 38 | Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. <i>Clinical Cancer Research</i> , 2017 , 23, 2584-2592 | 12.9 | 12 |
| 37 | Estrogen Receptor α as a Therapeutic Target in Breast Cancer Stem Cells. <i>Journal of the National Cancer Institute</i> , 2017 , 109, 1-14 | 9.7 | 48 |
| 36 | Digital image analysis outperforms manual biomarker assessment in breast cancer. <i>Modern Pathology</i> , 2016 , 29, 318-29 | 9.8 | 106 |
| 35 | Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells. <i>Oncotarget</i> , 2016 , 7, 35703-35723 | 3.3 | 28 |
| 34 | Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. <i>Scientific Reports</i> , 2016 , 6, 38037 | 4.9 | 13 |
| 33 | Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. <i>Cancer Research</i> , 2016 , 76, 3166-78 | 10.1 | 32 |
| 32 | Pericyte-fibroblast transition promotes tumor growth and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E5618-27 | 11.5 | 150 |
| 31 | Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms. <i>Annals of Diagnostic Pathology</i> , 2015 , 19, 203-10 | 2.2 | 3 |
| 30 | mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. <i>Cancer Letters</i> , 2015 , 367, 76-87 | 9.9 | 36 |

| | | | |
|----|--|------|-----|
| 29 | Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells. <i>Journal of the National Cancer Institute</i> , 2015 , 107, | 9.7 | 46 |
| 28 | Novel mechanism of macrophage-mediated metastasis revealed in a zebrafish model of tumor development. <i>Cancer Research</i> , 2015 , 75, 306-15 | 10.1 | 90 |
| 27 | Response to correspondence on Low concordance of biomarkers in histopathological and cytological material from breast cancer <i>Histopathology</i> , 2015 , 66, 756-8 | 7.3 | |
| 26 | Tumour nuclear oestrogen receptor beta 1 correlates inversely with parathyroid tumour weight. <i>Endocrine Connections</i> , 2015 , 4, 76-85 | 3.5 | 11 |
| 25 | Low concordance of biomarkers in histopathological and cytological material from breast cancer. <i>Histopathology</i> , 2014 , 64, 971-80 | 7.3 | 14 |
| 24 | miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. <i>Molecular Oncology</i> , 2014 , 8, 1690-702 | 7.9 | 58 |
| 23 | Oestrogen receptors α and β have divergent roles in breast cancer survival and lymph node metastasis. <i>British Journal of Cancer</i> , 2014 , 111, 918-26 | 8.7 | 18 |
| 22 | Superficial scrapings from breast tumors is a source for biobanking and research purposes. <i>Laboratory Investigation</i> , 2014 , 94, 796-805 | 5.9 | 7 |
| 21 | AmotL2 disrupts apical-basal cell polarity and promotes tumour invasion. <i>Nature Communications</i> , 2014 , 5, 4557 | 17.4 | 34 |
| 20 | Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo. <i>Breast Cancer Research</i> , 2014 , 16, R72 | 8.3 | 47 |
| 19 | Lymphoid aggregates in Crohn's colitis and mucosal immunity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 463, 637-42 | 5.1 | 8 |
| 18 | High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. <i>PLoS ONE</i> , 2013 , 8, e56795 | 3.7 | 95 |
| 17 | The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer. <i>BMC Cancer</i> , 2012 , 12, 79 | 4.8 | 4 |
| 16 | Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2601-8 | 2.2 | 321 |
| 15 | Current concepts and significance of estrogen receptor α in prostate cancer. <i>Steroids</i> , 2012 , 77, 1262-6 | 2.8 | 49 |
| 14 | Evidence of a functional estrogen receptor in parathyroid adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 4631-9 | 5.6 | 26 |
| 13 | Estrogen receptors α and β have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. <i>Molecular Endocrinology</i> , 2012 , 26, 1991-2003 | | 90 |
| 12 | ER α represses FOXM1 expression through targeting ER α to control cell proliferation in breast cancer. <i>American Journal of Pathology</i> , 2011 , 179, 1148-56 | 5.8 | 27 |

| | | | |
|----|--|------|------|
| 11 | FOXm1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. <i>Oncogene</i> , 2010 , 29, 2983-95 | 9.2 | 113 |
| 10 | Estrogen receptors in colorectal cancer: goalkeepers, strikers, or bystanders?. <i>Cancer Prevention Research</i> , 2010 , 3, 897-9 | 3.2 | 9 |
| 9 | Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. <i>Cancer Research</i> , 2009 , 69, 6100-6 | 10.1 | 153 |
| 8 | Estrogen receptor beta in breast cancer--diagnostic and therapeutic implications. <i>Steroids</i> , 2009 , 74, 635-41 | 2.8 | 100 |
| 7 | Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation. <i>Breast Cancer Research</i> , 2009 , 11, R79 | 8.3 | 25 |
| 6 | FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. <i>International Journal of Oncology</i> , 2009 , 35, 57-68 | 1 | 70 |
| 5 | Estrogen receptors: how do they signal and what are their targets. <i>Physiological Reviews</i> , 2007 , 87, 905-31 | 17.9 | 1266 |
| 4 | Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. <i>Cancer Research</i> , 2006 , 66, 11207-13 | 10.1 | 171 |
| 3 | HES-1 inhibits 17beta-estradiol and heregulin-beta1-mediated upregulation of E2F-1. <i>Oncogene</i> , 2004 , 23, 8826-33 | 9.2 | 50 |
| 2 | Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 1566-71 | 11.5 | 442 |
| 1 | Lithium chloride inhibits the expression and secretion of insulin-like growth factor-binding protein-1. <i>Journal of Endocrinology</i> , 2001 , 171, R11-5 | 4.7 | 11 |